Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

M. Roldo; E. Barbu; J.F. Brown; D.W. Laight; John Smart; J. Tsibouklis

doi:10.1002/jbm.a.30810

Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

M. Roldo, E. Barbu, J.F. Brown, D.W. Laight, John Smart, J. Tsibouklis

University of Brighton

Research output: Contribution to journal › Article

Abstract

Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006

Original language	English
Pages (from-to)	706-715
Number of pages	10
Journal	Journal of Biomedical Materials Research Part A
Volume	79A
Issue number	3
DOIs	https://doi.org/10.1002/jbm.a.30810
Publication status	Published - Jul 2006

Keywords

mucoadhesion
azopolymers
colon specific drug delivery
inflammatory bowel disease (IBD)
4,4′divinylazobenzene

Access to Document

10.1002/jbm.a.30810Licence: Unspecified

http://onlinelibrary.wiley.com/doi/10.1002/jbm.a.30810/abstractLicence: Unspecified

Cite this

@article{5031cf48655b49e7bf587d78adbaf4b8,

title = "Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study",

abstract = "Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material. {\textcopyright} 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006",

keywords = "mucoadhesion, azopolymers, colon specific drug delivery, inflammatory bowel disease (IBD), 4,4′divinylazobenzene",

author = "M. Roldo and E. Barbu and J.F. Brown and D.W. Laight and John Smart and J. Tsibouklis",

year = "2006",

month = jul,

doi = "10.1002/jbm.a.30810",

language = "English",

volume = "79A",

pages = "706--715",

journal = "Journal of Biomedical Materials Research Part A",

issn = "1549-3296",

number = "3",

}

TY - JOUR

T1 - Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

AU - Roldo, M.

AU - Barbu, E.

AU - Brown, J.F.

AU - Laight, D.W.

AU - Smart, John

AU - Tsibouklis, J.

PY - 2006/7

Y1 - 2006/7

N2 - Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006

AB - Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006

KW - mucoadhesion

KW - azopolymers

KW - colon specific drug delivery

KW - inflammatory bowel disease (IBD)

KW - 4,4′divinylazobenzene

U2 - 10.1002/jbm.a.30810

DO - 10.1002/jbm.a.30810

M3 - Article

SN - 1549-3296

VL - 79A

SP - 706

EP - 715

JO - Journal of Biomedical Materials Research Part A

JF - Journal of Biomedical Materials Research Part A

IS - 3

ER -

Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

Abstract

Keywords

Access to Document

Fingerprint

Cite this